Andrew Young
Founder at Phoundry Pharmaceuticals, Inc.
Profile
Andrew Young is the founder of Satiogen Pharmaceuticals, Inc. (founded in 2007) and Phoundry Pharmaceuticals, Inc. (founded in 2015, where he also holds the title of Director & Chief Scientific Officer).
He previously worked as Vice President-Research at Amylin Pharmaceuticals, Inc., as a Professor-Physiology Department at Auckland University, and as a Clinical Research Scientist at the National Institutes of Health from 1984 to 1987.
Dr. Young received his graduate and doctorate degrees from Auckland University.
Andrew Young active positions
| Companies | Position | Start |
|---|---|---|
Phoundry Pharmaceuticals, Inc.
 Phoundry Pharmaceuticals, Inc. BiotechnologyHealth Technology Phoundry Pharmaceuticals, Inc. engages in the discovery of peptide therapeutic drugs for metabolic diseases. The firm also provides drugs for diabetes and obesity diseases. The company was founded by Paul L. Feldman, Andrew Young, Ved Srivastava, Mark Paulik, James Way and Shane Roller in 2015 and is headquartered in Research Triangle Park, NC. | Founder | 31/12/2014 |
Former positions of Andrew Young
| Companies | Position | End |
|---|---|---|
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Chief Tech/Sci/R&D Officer | 31/12/1986 |
Satiogen Pharmaceuticals, Inc.
 Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Founder | - |
| Auckland University | Corporate Officer/Principal | - |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Andrew Young
| Auckland University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Satiogen Pharmaceuticals, Inc.
Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Commercial Services |
Phoundry Pharmaceuticals, Inc.
Phoundry Pharmaceuticals, Inc. BiotechnologyHealth Technology Phoundry Pharmaceuticals, Inc. engages in the discovery of peptide therapeutic drugs for metabolic diseases. The firm also provides drugs for diabetes and obesity diseases. The company was founded by Paul L. Feldman, Andrew Young, Ved Srivastava, Mark Paulik, James Way and Shane Roller in 2015 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Stock Market
- Insiders
- Andrew Young
